![Matthew Ros](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 191 000 $ in data 30/06/2026
Matthew E.
Ros is currently an Independent Director at Cogent Biosciences, Inc. since 2019.
Formerly, served as Chief Executive Officer & Director at Fore Biotherapeutics, Inc. from 2022 to 2023.
Worked at Bristol Myers Squibb Co. as Senior Director from 1990 to 2007.
Held the position of Senior Vice President-Commercial Operations at ARIAD Pharmaceuticals, Inc. from 2009 to 2010.
Was Vice President & Head-Franchise at Genzyme Corp.
from 2012 to 2014.
Served as Associate Vice President at Sanofi from 2010 to 2012 and later as COO, VP & Global Head-Oncology Business Unit at Sanofi from 2014 to 2016.
Held the role of Chief Financial Officer at Epizyme, Inc. in 2021.
Held a trustee position at Cancer Care, Inc. Served as Chief Operating Officer at Verastem, Inc. in 2025.
Education includes an undergraduate degree from The State University of New York, conferred in 1988.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
VERASTEM, INC. 0,08% | 01/04/2025 | 50.000 ( 0,08% ) | 191 000 $ | 30/06/2026 |
| 09/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| COGENT BIOSCIENCES, INC. | Direttore/Membro del Consiglio | 26/07/2019 |
| Società | Posizione | Fine |
|---|---|---|
| VERASTEM, INC. | Direttore operativo | 15/12/2025 |
Fore Biotherapeutics, Inc.
 Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology company that specializes in cancer therapies | Amministratore Delegato | 01/08/2023 |
| EPIZYME, INC. | Direttore Finanziario/CFO | 01/10/2021 |
| SANOFI | Direttore operativo | 01/05/2016 |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Corporate Officer/Principal | 01/12/2014 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 10 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes small-molecule drugs for the treatment of cancer | Health Technology |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Sanofi
 Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
Cogent Biosciences, Inc.
 Cogent Biosciences, Inc. BiotechnologyHealth Technology Discovers and develops new cellular immunotherapies for cancer | Health Technology |
Cancer Care, Inc.
 Cancer Care, Inc. Hospital/Nursing ManagementHealth Services Provides cancer treatment services | Health Services |
The State University of New York
 The State University of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Develops therapeutics for the treatment of patients with genetically defined cancers | Health Technology |
Verastem, Inc.
 Verastem, Inc. BiotechnologyHealth Technology Discovers and develops drugs | Health Technology |
Fore Biotherapeutics, Inc.
Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology company that specializes in cancer therapies | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
